Author:
Farrell Michael H.,Mooney Katherine E.,Laxova Anita,Farrell Philip M.
Abstract
Our objective was to develop and test a new approach to obtaining parental policy guidance about disclosure of incidental findings of newborn screening for cystic fibrosis (CF), including heterozygote carrier status and the conditions known as CFTR-related metabolic syndrome (CRMS) and/or cystic fibrosis screen positive inconclusive diagnosis, CFSPID. The participants were parents of infants up to 6 months old recruited from maternity hospitals/clinics, parent education classes and stores selling baby products. Data were collected using an anonymous, one-time Internet-based survey. The survey introduced two scenarios using novel, animated videos. Parents were asked to rank three potential disclosure policies—Fully Informed, Parents Decide, and Withholding Information. Regarding disclosure of information about Mild X (analogous to CRMS/CFSPID), 57% of respondents ranked Parents Decide as their top choice, while another 41% ranked the Fully Informed policy first. Similarly, when considering disclosure of information about Disease X (CF) carrier status, 50% and 43% gave top rankings to the Fully Informed and Parents Decide policies, respectively. Less than 8% ranked the Withholding Information policy first in either scenario. Data from value comparisons suggested that parents believed knowing everything was very important even if they became distressed. Likewise, parents preferred autonomy even if they became distressed. However, when there might not be enough time to learn everything, parents showed a slight preference for deferring decision-making. Because most parents strongly preferred the policies of full disclosure or making the decision, rather than the withholding option for NBS results, these results can inform disclosure policies in NBS programs, especially as next-generation sequencing increases incidental findings.
Funder
The Legacy of Angels Foundation
Subject
Obstetrics and Gynecology,Immunology and Microbiology (miscellaneous),Pediatrics, Perinatology and Child Health
Reference35 articles.
1. Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs;Grosse;Morb. Mortal. Wkly. Rep. Recomm. Rep.,2004
2. Newborn screening for cystic fibrosis. The methods compared on 229,626 newborns tested in 8 years in the Veneto Region;Pederzini;Riv. Ital. Pediatr.-Ital. J. Pediatrics,1983
3. Newborn Screening for CF across the Globe—Where Is It Worthwhile?
4. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years
5. Efficacy of Statewide Neonatal Screening for Cystic Fibrosis by Assay of Trypsinogen Concentrations
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献